Literature DB >> 3202561

Magnetic resonance imaging of the posterior cranial fossa.

G E Valvassori1, M Guzman.   

Abstract

Magnetic resonance imaging has acquired a leading role in the assessment of the posterior cranial fossa, base of the skull, and neck. Several technical improvements, such as further refinement of surface coils, fast scanning, and paramagnetic agents, have enhanced the diagnostic capability of this imaging technique. It is extremely useful in the differentiation of pathologic processes arising from or involving the petrous pyramids, such as congenital cholesteatomas, cholesterol granulomas, and glomus tumors. It is the study of choice for both extra- and intra-axial lesions in the posterior cranial fossa. The magnetic characteristics of the most common lesions are reviewed in this paper.

Entities:  

Mesh:

Year:  1988        PMID: 3202561     DOI: 10.1177/000348948809700604

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  5 in total

1.  Transmastoid infralabyrinthine approach to petrous temporal bone.

Authors:  D F Wilson; R S Hodgson
Journal:  Skull Base Surg       Date:  1991

2.  Petrous apex lesions.

Authors:  R G Amedee; G J Gianoli; W J Mann
Journal:  Skull Base Surg       Date:  1994

3.  Facial nerve neuromas: MR imaging. Report of four cases.

Authors:  N Martin; O Sterkers; D Mompoint; H Nahum
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

4.  Percutaneous inner-ear access via an image-guided industrial robot system.

Authors:  S Baron; H Eilers; B Munske; J L Toennies; R Balachandran; R F Labadie; T Ortmaier; R J Webster
Journal:  Proc Inst Mech Eng H       Date:  2010       Impact factor: 1.617

5.  Percutaneous access to the petrous apex in vitro using customized micro-stereotactic frames based on image-guided surgical technology.

Authors:  George B Wanna; Ramya Balachandran; Omid Majdani; Jason Mitchell; Robert F Labadie
Journal:  Acta Otolaryngol       Date:  2009-08-25       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.